133 related articles for article (PubMed ID: 38231469)
21. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
22. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Brady SW; Zhang J; Seok D; Wang H; Yu D
Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
[TBL] [Abstract][Full Text] [Related]
23. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
24. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
25. Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Kaczyńska A; Świerczyńska J; Herman-Antosiewicz A
Nutr Cancer; 2015; 67(6):976-86. PubMed ID: 26134366
[TBL] [Abstract][Full Text] [Related]
26. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
27. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Ding X; Sharko AC; McDermott MSJ; Schools GP; Chumanevich A; Ji H; Li J; Zhang L; Mack ZT; Sikirzhytski V; Shtutman M; Ivers L; O'Donovan N; Crown J; Győrffy B; Chen M; Roninson IB; Broude EV
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2201073119. PubMed ID: 35914167
[TBL] [Abstract][Full Text] [Related]
29. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L; Curigliano G; Minisini AM; Cinieri S; Tondini CA; D'Hollander K; Arpino G; Bernardo A; Martignetti A; Criscitiello C; Puglisi F; Pestrin M; Sanna G; Moretti E; Risi E; Biagioni C; McCartney A; Boni L; Buyse M; Migliaccio I; Biganzoli L; Di Leo A
Ann Oncol; 2018 Aug; 29(8):1748-1754. PubMed ID: 29893790
[TBL] [Abstract][Full Text] [Related]
32. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis.
Li J; Zhu F; Lubet RA; De Luca A; Grubbs C; Ericson ME; D'Alessio A; Normanno N; Dong Z; Bode AM
Mol Carcinog; 2013 Feb; 52(2):134-43. PubMed ID: 22086611
[TBL] [Abstract][Full Text] [Related]
33. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
34. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
35. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
[TBL] [Abstract][Full Text] [Related]
36. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
[TBL] [Abstract][Full Text] [Related]
37. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis.
Lei L; Huang Y; Shi L; Ye W; Lv X; Ying L; Yu X; Cheng SH; Zheng Y
Breast Cancer Res Treat; 2024 Feb; 203(3):613-625. PubMed ID: 37924380
[TBL] [Abstract][Full Text] [Related]
39. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
